Metropolis Q1 FY27: Volume-led growth lifts margins as Metropolis 3.0 takes shape

Metropolis Healthcare opened FY27 with a quarter that looked clean on both growth and profitability. Revenue from operations rose to INR 450 Cr in Q1 FY27, up 16.6 percent year on year. EBITDA increased faster at INR 113 Cr, up 27.1 percent, pushing the EBITDA margin to 25.2 percent from 23.1 percent last year. Profit after tax came in at INR 57 Cr, up 25.8 percent, with PAT margin improving to 12.6 percent.

The standout in management commentary was the quality of growth. The company said it delivered mid-teen revenue growth despite no price hikes. That points to demand and throughput rather than pricing doing the heavy lifting. The operating result reflected the same theme. Margin expansion was attributed to operating leverage, automation, and process efficiencies. The quarter also benefited from network scaling, even as Metropolis rationalised and consolidated parts of the footprint.

Demand stayed broad-based across channels and test mix

The business continued to be balanced between consumer and institutional demand. B2C revenue was INR 257 Cr, up 18 percent year on year, while B2B revenue was INR 193 Cr, up 15 percent. B2C remained the larger channel at 57 percent of revenue, with B2B contributing 43 percent.

Growth was backed by higher patient and test volumes. Patient volume increased to 3.69 Mn from 3.35 Mn, a 10 percent rise. Test volume grew 11 percent to 7.83 Mn from 7.07 Mn. Monetisation improved as well, even in the absence of price hikes, likely reflecting mix and premiumisation. Revenue per patient rose 6 percent to INR 1,219 and revenue per test increased 5 percent to INR 575.

Within the revenue mix, Specialty remained the largest contributor at 40 percent, followed by Semi-specialty at 25 percent, TruHealth at 18 percent, and Routine at 17 percent. Growth rates were led by TruHealth at 22 percent, then Specialty at 17 percent, Semi-specialty at 15 percent, and Routine at 13 percent. This is a helpful combination because it shows the company is not leaning on only one engine. Preventive and wellness is growing fast, but Specialty still anchors the overall mix.

TruHealth revenue was INR 81 Cr in Q1 FY27, up 22 percent. The company highlighted that radiology-integrated wellness packages grew 40 percent plus through range optimisation and upselling. Premium TruHealth packages grew 50 percent plus, supported by consult, vitals, and ECG-led extensions. Metropolis also launched AI-enabled personalised nutrition and a TruHealth Mind and Body offering for cognitive wellness, and introduced dedicated Wellness Zones at marquee centres for consultative wellness delivery.

Specialty revenue stood at INR 178 Cr, up 17 percent. Management commentary focused on clinician trust and scientific expansion. The company expanded high-end genomics adoption and launched a 1,000-gene oncology panel. It also pointed to leadership across chronic diagnostics such as allergy, autoimmunity, diabetes, and cardiology, and the scaling of the Core Diagnostics test menu across B2C and B2B networks. Digital promotion of high-end specialty tests was cited as a driver for reach and realisation.

Reach expanded, but with active network hygiene

Metropolis continues to widen access, with presence across about 750 towns. The company also said Tier III cities delivered about 25 percent revenue growth, and Tier III contribution to domestic revenue stood at 26 percent. Tier I remained the largest contributor at 67 percent, while Tier II was 7 percent.

Regionally, West contributed 50 percent of domestic revenue, followed by South at 27 percent, North at 18 percent, and East at 6 percent. North India stood out on growth at 19 percent, and the company noted North contribution rose to 18 percent from 17 percent. Tier III growth was reported at 25 percent, higher than Tier I at 11 percent and Tier II at 14 percent. For investors, the key point is not only that expansion is happening, but that it is happening where organised diagnostics can gain share from fragmented players.

Infrastructure data shows a network that is still scaling while being optimised. The consolidated laboratory network was 209 in Q1 FY27, down from 212 in FY26, because the company consolidated 7 labs with acquired entities. Service network stood at 5,003, compared with 5,026 in FY26. In the quarter, Metropolis added 295 service points but rationalised 318 non-productive centres. The centre to lab ratio improved to 24:1 from 21:1 last year, suggesting higher utilisation and better alignment between collection points and processing capacity.

The channel narrative also stayed consistent. B2C growth was attributed to micro-marketing strategies and brand pull, with Tier III and beyond expansion widening reach. Digital, app and AI-led initiatives were highlighted as improving TruHealth conversion. Premiumisation efforts were tied to vitals, consult, and ECG offerings. On the B2B side, Metropolis focused on improving business quality, service excellence, and widening the clinician and institutional network.

Metropolis 3.0: growth framed around technology, science, and governance

Beyond quarterly numbers, the presentation positioned the next phase as Metropolis 3.0. The stated ambition is profitable, science-led growth, strengthening the core, expanding into adjacencies, and building shareholder value. The pillars were clear: lead with technology, differentiate scientifically, deliver consistent profitable growth, and protect the brand promise under strong governance.

The technology agenda is being built as a stack rather than a single initiative. The company outlined a second-generation point of sale platform for registration and invoicing, a partner portal to manage partner life-cycle and engagement, a customer data platform for a 360 degree customer view using AI to personalise experiences, and a sales CRM with CPQ to manage dynamic pricing. It also highlighted enterprise-grade security with DDPD-compliant patient data handling. The practical implication is that Metropolis is treating technology as both a cost lever and a growth lever, improving productivity, partner scalability, and customer experience while keeping data security in focus.

Scientific differentiation remains a central part of the story. Metropolis added 36 new tests in Q1 FY27 and had added 347 tests in FY26, including the integration of the Core menu. It reported a 99 percent EQAS external quality assurance score and 99.99 percent report accuracy, with 100 percent labs under CAP, NABL, KENAS or benchmarked. The company highlighted growth in NGS and molecular genomics driven by in-house testing and AI-enabled genetic reporting. It also pointed to centres of excellence in Women and Child Health and Oncology.

The presentation also described industry-first initiatives: a patented Clinician Decision Support System called TB Metrobot, scientific advisory around next best action for chronic disease management, and the creation of a Clinician Support Vertical for Genomics and a Metrodocs membership program. For investors, these elements matter because they protect the premium end of diagnostics, where quality, interpretation, and trust can sustain pricing and volume even in competitive markets.

Market structure supports organised share gains, but execution is the differentiator

Metropolis is operating in a diagnostics market that still has a large unorganised component. The presentation cited India diagnostic labs market size at about US$11.0 bn in 2025, projected to grow at about 11 percent CAGR to US$28.5 bn by 2034E. In 2025, market structure was estimated at 48 percent standalone or unorganised labs, 37 percent hospital-based labs, and only 15 percent organised chains.

The company’s commentary on what is driving the shift to organised providers lines up with its execution priorities: accreditation and consistency building trust, home sample collection and digital reports widening access, and deeper Tier II and Tier III penetration alongside rising preventive and wellness testing. The quarter’s metrics show the operating model is aligned to this shift. Volumes are rising, the network is expanding into smaller cities, and higher-value categories such as specialty and wellness are growing without relying on price hikes.

Profitability in Q1 FY27 also suggests that scaling is translating into financial leverage. Total cost rose to INR 337 Cr from INR 297 Cr, but EBITDA grew faster than revenue. Depreciation increased modestly, while finance cost rose to INR 8.3 Cr from INR 4.6 Cr. Other income was lower at INR 5.1 Cr versus INR 7.5 Cr. Despite these moving parts, PAT still rose at about 26 percent year on year. That is a sign that the core operating performance, rather than non-operating support, carried the quarter.

Takeaways for investors

Q1 FY27 reinforced a simple theme: Metropolis is growing on throughput and mix, not on pricing. Revenue grew 17 percent, while EBITDA grew 27 percent and margins expanded by 210 bps. Patient and test volumes remained in double digits, and revenue per patient and per test also improved.

The mix continues to tilt toward higher-value areas. Specialty remains 40 percent of revenue with 17 percent growth, and TruHealth is 18 percent of revenue with 22 percent growth, supported by premium packages and new wellness offerings. The company is also expanding reach with a presence across about 750 towns and strong Tier III growth, while keeping network hygiene through rationalisation of non-productive centres and consolidation of labs.

Metropolis 3.0 ties these actions into a broader plan built on technology, scientific differentiation, disciplined growth, and governance. In a market where organised chains still represent a small share, consistent execution on quality, access, and experience is what can translate industry tailwinds into durable shareholder returns.